MS
OLMA icon

Maven Securities’s Olema Pharmaceuticals OLMA Stock Holding History

Maven Securities’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,345
Closed -$78K – 1241
2021
Q1 		$78K Sell
2,345
-3,254
-58% -$139K ﹤0.01% 1036
2020
Q4 		$278K Buy
+5,599
New +$263K 0.03% 437

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Maven Securities's OLMA Position: Q2 2021 in Review

Maven Securities sold out of Olema Pharmaceuticals (OLMA) in Q2 2021, closing a stake of 2,345 shares — an estimated $78K sold.

Maven Securities first reported a position in OLMA in Q4 2020 and held it in 2 quarters. The position peaked at $278K in Q4 2020. 69 funds tracked by Wall St. Rank hold OLMA as of Q2 2021.

  • Maven Securities reported no remaining Olema Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 2,345 Olema Pharmaceuticals shares in Q2 2021, an estimated $78K.
  • Maven Securities first reported a position in Olema Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Maven Securities's Olema Pharmaceuticals position peaked at $278K in Q4 2020.
  • 69 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.